Medical Condition News

RSS

Study: p63 gene stifles spread of cancer

Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.

21 Oct 2010

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

21 Oct 2010

Aqueous cream worsens eczema: Study

Researchers claim that a cream that is often used in a skin condition called eczema may actually make the condition worse. The research conducted at Bath University found that aqueous cream thinned the skin after a few weeks of use. They found that the cream contains a detergent rather than just moisturizers. The team also said that most GPs seemed unaware of official advice not to prescribe the cream as a moisturizer.

21 Oct 2010

Joint stem cell study to investigate multiple sclerosis

A $2.2 million project by Victorian and Californian researchers will assess whether stem cell therapies can be used to combat diseases such as Multiple Sclerosis and Type-1 diabetes, and help organ transplant recipients. Speaking at AusBiotech 2010 in Melbourne today, Innovation Minister Gavin Jennings said the Brumby Labor Government had contributed $575,505 to the project, the fifth to be funded through the $28 million Victoria–California Stem Cell Alliance which was established in 2008 under the Biotechnology Strategic Development Plan.

21 Oct 2010

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

A new way to pay for chemotherapy

Kaiser Health News staff writer Julie Appleby reports: "One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines - and limit profits doctors make by dispensing in-office chemotherapy drugs" (Appleby, 10/20).

21 Oct 2010

Dopamine vital for rhythmic expression in specific brain regions: Research

Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2. Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.

21 Oct 2010

Beaumont Hospital announces opening of new Ernst Cardiovascular Center

Beaumont Hospitals' world renowned heart center has expanded and enhanced its services with the Oct. 18 opening of the new Ernst Cardiovascular Center at Beaumont Hospital, Royal Oak.

21 Oct 2010

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion Pharmaceuticals, Inc. today announced that its two open-label Phase 2 studies investigating eculizumab (Soliris) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) have met the primary and key secondary endpoints with high clinical and statistical significance, in interim analyses.

21 Oct 2010

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

20 Oct 2010

Cipla launches generic Pirfenidone for IPF

Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF.

20 Oct 2010

Health Impact Project announces $400,000 in grants to 4 organizations to conduct health impact assessments

The Health Impact Project, a collaboration of the Robert Wood Johnson Foundation and The Pew Charitable Trusts, today announced nearly $400,000 in grants to four organizations to conduct health impact assessments (HIAs). The assessments will identify and address potential and often overlooked health implications of policy proposals including farm-to-school food legislation, energy development, smart-metering technology for electric utilities and urban transportation plans.

20 Oct 2010

CASLPA celebrates International Stuttering Day on October 22

King George VI recognized the importance of speech therapy to treat his stuttering nearly 100 years ago, and it is just as important today. The Canadian Association of Speech-Language Pathologists and Audiologists celebrates the important work of speech-language pathologists to help people who stutter on International Stuttering Day October 22.

20 Oct 2010

New online community to discuss weight loss management

Frank Cruz has been at the forefront of a campaign to stop the spread of obesity in America. In an effort to give people a chance to share their stories and struggles with weight, Frank began blogging on the website "Fat Man Unleashed," an online community of voices who have all battled with what Frank calls, "The Yo-yo Life."

20 Oct 2010

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

20 Oct 2010

BREAKYL drug receives European approval

BioDelivery Sciences International, Inc. and Meda today announced approval of BEMA Fentanyl in Europe via the Decentralized Procedure, with Germany acting as Reference Member State.

20 Oct 2010

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

Aradigm Corporation today announced positive top line data from its recently concluded 6-month Phase 2b study (ORBIT-2) with Aradigm's once-daily dual release ciprofloxacin for inhalation (DRCFI, ARD-3150) in patients with non-cystic fibrosis bronchiectasis.

20 Oct 2010